Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

This study is not yet open for participant recruitment.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Lymphoma
2		Additional conditions recognized in this trial
			Lymphoma, B-Cell
3		More general conditions related to this trial
			Immune System Diseases
			Immunoproliferative Disorders
			Lymphatic Diseases
			Lymphoma, Non-Hodgkin
			Lymphoproliferative Disorders
			Neoplasms
			Neoplasms by Histologic Type
4		Interventions listed in this trial
			cyclophosphamide
			doxorubicin hydrochloride
			lenalidomide
			pegfilgrastim
			prednisone
			rituximab
			vincristine
			laboratory biomarker analysis
			polymorphism analysis
5		Additional drug interventions recognized in this trial
			Doxorubicin
6		More general drug interventions related to this trial
			Alkylating Agents
			Anti-Inflammatory Agents
			Antibiotics, Antineoplastic
			Antimitotic Agents
			Antineoplastic Agents
			Antineoplastic Agents, Alkylating
			Antineoplastic Agents, Hormonal
			Antineoplastic Agents, Phytogenic
			Antirheumatic Agents
			Glucocorticoids
			Hormones
			Hormones, Hormone Substitutes, and Hormone Antagonists
			Immunologic Factors
			Immunosuppressive Agents
			Mitosis Modulators
			Molecular Mechanisms of Pharmacological Action
			Myeloablative Agonists
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
			Tubulin Modulators
7		Sponsors listed in this trial
			Mayo Clinic
			National Cancer Institute (NCI)